14-day Premium Trial Subscription Sign Up For FreeGet Free

$46.51 (-2.19%)

Volume: 80k

Closed: Jan 25, 2022

Hollow Logo Score: -1.591

Eagle Pharmaceuticals Stock Forecast

$46.51 (-2.19%)

Volume: 80k

Closed: Jan 25, 2022

Score Hollow Logo -1.591

Eagle Pharmaceuticals Company Profile

50 Tice Boulevard

Woodcliff Lake NJ 07677




Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer and mesothelioma; and EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE